image dons

I make a donation

AMUNDSEN

Evolocumab or Normal strategies to reach guidelines LDL objectives in patients with acute myocardial infarction treated by percutaneous coronary intervention

En cours

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

logo étude

objectif

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs. Standard of Care as defined by the guidelines but also constrained by current drug availabilities in the different participating countries.

date de réalisation

2021

nombre de patients

1666

nombre de centres participants

International multicentric trial

type de financement

Private (Fonds de Dotation ACTION) & Amgen)

Référence

EUDRACT : 2021-000573-80

A study conducted by Fonds de Dotation ACTION.
Find out details and results on the dedicated page

AMUNDSEN conducted by Fonds de Dotation ACTION

Autres études

+

ACORES-2

En cours


Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.
+

AMUNDSEN

En cours


A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....
+

ANCHOR

En cours


Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients